Prevalence and outcome of acute gastrointestinal injury in critically ill patients

A systematic review and meta-analysis

Dong Zhang, MD, PhD, Yuting Li, MD, Lili Ding, MD, Yao Fu, MD, PhD, Xuechao Dong, MD, PhD, Hongxiang Li, MD, PhD^{*}

Abstract

Background: The aim of the study was to investigate the prevalence and impact of acute gastrointestinal injury (AGI) on clinical outcomes in critically ill patients.

Methods: The PubMed, Cochrane, and Embase databases were searched to identify trials that assessed gastrointestinal injury in critically ill patients. Outcome measures were prevalence of AGI among critically ill patients; incidence of mortality among critically ill patients with AGI, and incidence of mortality stratified by severity of AGI.

Results: The meta-analysis included 14 studies. The prevalence of AGI in critically ill patients was 40% [95% confidence interval (CI), 27%–54%]; the incidence of mortality among critically ill patients with AGI was 33% (95% CI, 26%–41%). There was a higher risk of mortality in critically ill patients with AGI compared to those without AGI [risk ratio (RR) = 2.01; 95% CI 1.20–3.37, P = .008). Subgroup analyses of studies that defined AGI according to European Society of Intensive Care Medicine (ESICM) criteria confirmed these findings and showed that the risk of mortality was higher in critically ill patients with more severe AGI (ESICM grade III and IV vs grade II) [RR of 1.86 (95% CI 1.48–2.34), P < .00001].

Conclusion: AGI is common in critically ill patients, mortality in critically ill patients with AGI is high, and severity of AGI is associated with mortality. The widespread clinical use of standard criteria with a severity gradation will facilitate the diagnosis and management of AGI in critically ill patients.

Abbreviations: AGI = acute gastrointestinal injury, CI = confidence interval, ESICM = European Society of Intensive Care Medicine, GI = gastrointestinal, ICU = intensive care unit, MODS = multiple organ dysfunction syndrome, NOS = Newcastle-Ottawa scale, RR = risk ratio, SOFA = Sequential Organ Failure Assessment, WGAP = Working Group on Abdominal Problems.

Keywords: acute gastrointestinal injury, classification, mortality, prevalence

1. Introduction

The gastrointestinal (GI) tract is a complex organ system that performs digestive, absorptive, excretory, immune, endocrine, and barrier functions. GI symptoms occur in approximately 62% of patients in the intensive care unit (ICU), and may influence clinical outcomes.^[1]

Traditionally, GI dysfunction or acute gastrointestinal injury (AGI) was evaluated based solely on the presence or absence of any specific GI symptom. In 2012, the Working Group on Abdominal Problems (WGAP) of the European Society of Intensive Care Medicine (ESICM) proposed a definition of AGI in intensive care patients as malfunctioning of the GI tract in

Medicine (2018) 97:43(e12970)

Received: 4 June 2018 / Accepted: 2 October 2018 http://dx.doi.org/10.1097/MD.000000000012970 critically ill patients due to their acute illness. Four grades of severity were identified: AGI grade I, a self-limiting condition with future risk of GI dysfunction or failure; AGI grade II (GI dysfunction), interventions are required to restore GI function; AGI grade III (GI failure), interventions cannot restore GI function; AGI grade IV, GI failure that is immediately life threatening.^[1]

Although some studies have found the AGI grading scale is applicable for identifying the severity of GI dysfunction and could be used as a predictor of poor prognosis in patients in the ICU,^[2,3] others suggest that AGI has no influence on mortality in this patient population.^[4] The objective of this meta-analysis was to investigate the impact of AGI, using past definitions and that proposed by the ESICM WGAP, on clinical outcomes in critically ill patients.

2. Materials and methods

This systematic review and meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^[5] Ethical approval was not necessary for this study because it was a review of the published literature.

2.1. Search strategy

Two review authors independently searched the PubMed, Cochrane, and Embase databases from inception to the 31st

Editor: David Burmeister.

The authors report no conflicts of interest.

Supplemental Digital Content is available for this article.

ICU, First Hospital of Jilin University, Changchun, China.

^{*} Correspondence: Hongxiang Li, ICU, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun, China (e-mail: yaloos@sina.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

of July 2017 using the following search terms: "feeding intolerance," "food intolerance," "feed intolerance," "enteral tolerance," "gastric tolerance," "gastrointestinal tolerance," "gastrointestinal symptoms," "gastrointestinal injury," "gastrointestinal dysfunction," "critical care," "critical illness," "intensive care," "intensive care unit," "ICU," and "critically ill." A manual search of the reference lists from relevant articles was also carried out. The search was limited to publications in the English language. The search strategy for each database is summarized in Supplement 1, http://links.lww.com/MD/C578.

2.2. Inclusion and exclusion criteria

Inclusion criteria were study design: prospective or retrospective observational cohort studies; population: any critically ill patients with AGI identified according to clearly defined criteria; intervention: consistent protocol of enteral feeding across patients with or without GI dysfunction; outcomes: mortality.

Exclusion criteria were reviews, letters, abstracts, or editorials; studies that reported insufficient data; and studies that only included patients with burns or malignancy.

In this study, AGI and its 4 grades of severity were defined according to the recommendations of the ESICM WGAP, except AGI grade I, which was considered non-AGI.^[1]

2.3. Data extraction

Two review authors independently examined titles and abstracts to select eligible studies. The full text of potentially relevant studies was retrieved and examined to determine which studies met the inclusion criteria. Disagreements about the study selection were resolved by discussion and consensus.

Two review authors independently extracted data from eligible studies, including study design and setting, study inclusion criteria, definition of GI dysfunction, AGI classification (if available), and incidence of mortality in the ICU. Disagreements about data extraction were resolved by discussion and consensus.

2.4. Quality assessment

Two review authors independently assessed the methodological quality of the included studies using the Newcastle-Ottawa scale (NOS),^[6] which allocates a maximum of 9 points according to the quality of the selection, comparability, and outcomes of the study populations. Study quality was defined as poor (0–3), fair (4–6), or good (7–9). Publication bias was not assessed, because each pooled estimate included <10 studies.

Disagreements about assessment of methodological quality were resolved by discussion and consensus.



Figure 1. Flow chart of the study selection.

Characteris	tics of the in	cluded stud	ies.									
Authors (years)	Study period	Country	Study design	Sample size	Age, year	Male (%)	APACHE II score	Inclusion criteria	Criteria of AGI	Proportion of AGI	Mortality in patients with AGI in the ICU	Main results
Chang (1987) ^[3]	1984–1985	Saudi Arabia	Single-center, ret- rospective cohort study	208	R	R	17.7	Critically ill patients	Failure to tolerate EN due to at least 1 of the following: vomining, a volume of aspirate approximating the amount of enteral feed infused, abdominal distension or diarrhea	97 (46.6%)	49 (50.5%)	GI dysfunction affected prognosis
Montejo (1999) ^[9]	Feb 1994	Spain	Multicenter, pro- spective cohort study	400	56.6±0.9	NN	18 (14–22)	Critically ill patients	Feeding intolerance with at least 1 of the following: abdominal disten- tion, high gastric residuals, vomiting and dier regurgitation, diamea, con-	251 (62.8%)	78 (31%)	Enteral nutrition-related Gl complications increased patient mortality
Mentec (2001) ^[10]	1997–1999	France	Single-center, prospective cohort	153	65 ± 15	86 (56%)	R	Critically ill patients	High gastric residuals or vomiting during EN	70 (46%)	29 (41%)	Upper digestive intolerance was associated with
Reintam (2006) ^[11]	2002	Germany and Estonia	Nulticenter, retro- spective cohort	2588	64 (55–72)	1692 (65.4%)	13 (9–17)	Critically ill patients (mainly cardiosurgical	Food intolerance, GI hemorrhage, or ileus during ICU stay	252 (9.7%)	110 (43.7%)	Ingular too mortainty GI failure increased ICU mortality.
Reintam (2008) ^[12]	2006-2007	Estonia	suudy Single-center, prospective cohort study	264	53.8±20.0	166 (62.9%)	14.2±7.7	patients with Patients with mechanical ventilation staying for >24 h	GIF score >=1 (EN<50% of needs) in 72 h	173 (65.5%)	35 (20.2%)	GI dysfunction during the first 3 days in the ICU had high prognostic value
Shimizu (2011) ^[13]	R	Japan	Single-center, prospective cohort study	63	58.8±20.7	33 (52.4%)	R	Critically ill patients with systemic inflam- matory response syn- drome and C-reactive protein level > 10 mg/	More than 300 mL of reflux in the first 24h during EN	14 (22.2%)	9 (47.4%)	of the involution dynamic and any any and any
Bejarano (2013) ^[15]	2005-2009	Spain	Single-canter, prospective cohort study	72	57.7 (17– 88)	48 (66.7%)	13.6±6.0	Critically III patients	Receiving <80% of the prescribed diet in 72h with at least 1 of the following: abdominal pain, abdominal distention, wontling and/or regurgi- tation, high gastric residual, pulmon- ary aspiration, diarrhea, or constipation in the first 72 h during	21 (29.2%)	9 (42.9%)	The baseline IAP with the APACHE II score can predict the tolerance of EN
Nguyen (2013) ^{(14]}	2010	Canada	Multicenter, pro- spective cohort study	248	Я	149 (60.1%)	R	Critically ill patients with mechanical ven- tilation staying for >48 h	The absence of a bowel movement for 3 or more days from the onset of entrain feeding pin is consipation and one of the following: illeus feed intolerance (feeds held for gastric residuals or vomiting), abdominal disention, masogastric tube insertion for decommension	50 (20.2%)	13 (26%)	Impaired GI transit is a common complication of critical lilmess and is associated with significant morbidity
Reintam [*] (2014) ^[16]	2004-2011	Estonia	Single-center, ret- rospective cohort	1712	59 (18–98)	1079 (73.0%)	14 (10–21)	Critically ill patients	EN percentage of estimated caloric needs was <80% during the first 3	897 (52.4%)	113 (12.6%)	Feeding intolerance is associated with increased
Gungabissoon (2014) ^[17]	2009	21 Countries	Multicenter, retro- spective cohort study	1888	57.57± 17.62	1145 (60.6%)	23.1±8.02	Critically ill patients with mechanical ven- tilation	Eed intolerance as large gastric residual volume, abdominal disten- sion, voniting/emesis, diarrhea, or e. or intervisor disconstort	576 (30.5%)	177 (30.8%)	Feeding intolerance is associated with poorer nutrition and clinical
Zhang (2014) ^[18] †	2012–2013	China	Single-center, ret- rospective cohort study	133	56.9 ± 18.2	64 (48.1%)	16.7±8.1	Critically ill patients	aujoure uncommun. AGI grade II or higher	45 (33.8%)	19 (42.2%)	AGI grading system can provide a preliminary assessment regarding
Li (2016) ^[3]	2014	China	Multicenter, pro- spective cohort study	196	66.0 (47.0– 80.0)	1 29 (65.8%)	16.0 (10.0– 23.0)	Critically ill patients with AGI	AGI grade II or higher	N	28 (26.4%)	AGI grading system does reflect the severity of illness and can predict short-term mortality in critically ill patients
												(continued)

3

Table 1

/uthors /ears)	Study period	Country	Study design	Sample size	Age, year	Male (%)	APACHE II score	Inclusion criteria	Criteria of AGI	Proportion of AGI	Mortality in patients with AGI in the ICU	Main results
.i (2017) ^[4]	2014	China	Single-center, prospective cohort study	06	66.0 (47.0– 80.0)	69 (76.7%)	20.0 (16.0– 22.0)	Critically ill patients with AGI	AGI grade II or higher	NR	13 (18.6%)	AGI grading system does not predict short-term mortality in critically ill
łu (2017) ^{[2]†}	2014	China	Multicenter, pro- spective cohort study	550	64.9±17.2	383 (69.6% 0	Я	Critically ill patients	AGI grade II or higher	355 (64.5%)	124 (34.9%0	Adl grading scheme is userti for identifying the severity of GI dysfunction and could be used as a predictor of impaired outcomes

2.5. Statistical analysis

Statistical analyses were performed using Review Manager Version 5.3 (RevMan, Cochrane Collaboration). For incidence outcomes, the reported incidence and standard deviation for AGI were calculated, and inverse variance was used to represent incidence as a risk difference. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous variables. A random-effects model was used to pool studies with significant heterogeneity, as determined by the chi-squared test ($P \le .10$) and inconsistency index ($I^2 \ge 50\%$).^[7] Subgroup analyses were conducted using the subset of studies that defined AGI according to ESICM WGAP criteria. A sensitivity analysis was performed, omitting 1 study at a time, to investigate the effect of each study on the association between AGI and mortality. P < .05 was considered statistically significant.

3. Results

3.1. Study characteristics and quality assessment

The search identified 393 articles. The titles and abstracts were screened, and 29 studies were considered potentially eligible for inclusion. Full-text articles were retrieved. After analyzing these full-text articles, 15 studies were excluded. Among these studies, 7 studies lacked mortality data, 7 studies lacked a control group, and 1 study used different enteral feeding protocols for patients with AGI and controls. Finally, 14 studies^[2–4,8–18] were found to be eligible for inclusion in our review (Fig. 1).

The characteristics of the included studies are shown in Table 1. A total of 14 eligible studies were published between 1987 and 2017. Among these studies, 4 studies were conducted in China, 6 studies were conducted in Europe, 1 study was conducted in Japan, 1 study was conducted in Saudi Arabia, 1 study was conducted in Canada, and 1 study involved 21 countries. A variety of criteria were used to define AGI. Among the included studies, only 4 studies applied the ESICM WGAP criteria. Overall, these studies included 8565 patients; of these, 2977 patients experienced AGI. The methodological quality of the included studies was good, and the mean NOS score was 8.5 (Table 2).

3.2. Prevalence of AGI

Two studies^[2–4,18] did not include a control group; therefore, the prevalence of AGI in critically ill patients is reported in 12 studies^[2,8–18] (n=8279 patients; of these, 2081 patients experienced AGI). The meta-analysis estimated the prevalence of AGI in these critically ill patients at 40% (95% CI: 27%–54%). There was evidence of substantial heterogeneity between studies (P < .00001, $I^2 = 99\%$; Fig. 2).

3.3. Mortality associated with AGI

The incidence of mortality in critically ill patients with AGI is reported in 14 studies^[2–4,8–18] (n=2977 patients with AGI). The meta-analysis estimated the incidence of mortality among these critically ill patients with AGI at 33% (95% CI: 26%–41%). There was evidence of substantial heterogeneity between studies (P < .00001, $I^2 = 95\%$; Fig. 3).

Risk of mortality in critically ill patients with AGI is reported in 12 studies (n = 7579 patients; of these, 2801 patients experienced AGI).^[2,8–18] The meta-analysis demonstrated a higher risk of mortality in critically ill patients with AGI compared to those

AGI includes AGI grade II, III, and IV; patients with AGI grade I were considered non-AGI

Adequacy of follow up of cohorts

-vollo⁻

enough long

Assessment

basis of the design

was not present at start of study

Ascertainment

nonexposed cohort

Representativeness of

exposed cohort

Reference (Year)

\$ \$ -☆ -☆ -☆ \$₹ -☆ \$ -☆ ☆ -☆

\$ \$ 43 ***

Reintam (2006)^[11] Reintam (2008)^[12]

Shimizu (2011)^[13] Bejarano (2013)^[4] Nguyen (2013)^[14]

Montejo (1999)^[10]

Ventec (2001)^[5] Chang (1987)^[9]

-☆

of exposure

or analysis

☆

Comparability of

Demonstration that outcome

Comparability

cohorts on the

of outcome

13 13 ₹3 ₹3 ₹3 33 ₹3 33 ₹3 ₹3 ☆ * * *

Outcome

Total score

\$ \$ -☆ 43 -☆

ထတထထတထတတထ

-☆ -☆ 13 4 \$

公公 公公 公公

☆

* * * * * * *

なな なな なな

₹3 3 ₹3 ₹3 3 1 1 1

-☆ -☆ 47

なな

1

Gungabissoon (2014)^[16]

Zhang (2014)^{[17}

Li (2016)^[3] Li (2017)^[18] Hu (2017)^[2]

Reintam (2014)^[15]

without A	GI (RR: 2.01, 95	% CI: 1.20-3.3	7, P = .008). There v	vas
evidence	of	substantial	heterogeneity	between	studies	(P
<.00001,	I^2 =	=96%; Fig. 4	ł).			

3.4. Subgroup analyses

Four studies^[2-4,18] that defined AGI according to ESICM WGAP criteria (n=969 patients; of these, 576 patients experienced AGI) were included in the subgroup analysis.

Two of these studies^[2,18] reported the incidence of AGI and risk of mortality. The meta-analysis estimated the incidence of AGI defined according to ESICM WGAP criteria in critically ill patients at 49% (95% CI: 19%-79%; Fig. 2), and demonstrated that the risk of mortality was higher in critically ill patients with AGI defined according to ESICM WGAP criteria compared to those without AGI (RR: 2.22, 95% CI: 1.36-3.63, P=.001; Fig. 4). There was evidence of substantial heterogeneity between studies (incidence estimate: P < .00001, $I^2 = 98\%$; mortality estimate: P = .15, $I^2 = 52\%$).

All 4 studies reported the incidence of mortality stratified according to the grade of AGI severity (grade III and IV vs grade II), as defined by the ESICM WGAP (n=576 patients with AGI; of these, 201 patients experienced AGI grade III and IV, and 375 patients experienced AGI grade II). The metaanalysis demonstrated a higher risk of mortality in critically ill patients with AGI grade III and IV, compared to those with AGI grade II (RR: 1.86, 95% CI: 1.48–2.34, P<.00001). There was no evidence of heterogeneity between studies $(P=.98, I^2=0\%, Fig. 5).$

3.5. Publication bias and sensitivity analysis

Publication bias was not assessed, because each pooled estimate included <10 studies.

Sensitivity analysis that omitted 1 study at a time produced RRs between 1.66 (1.25–2.21) and 2.21 (1.29–3.79), indicating that the results of this meta-analysis are robust.

4. Discussion

This meta-analysis was conducted to investigate the impact of AGI on clinical outcomes in critically ill patients. The findings revealed a higher risk of mortality in critically ill patients with AGI compared to those without AGI. In addition, mortality risk was increased in critically ill patients with more severe AGI, compared to patients with less severe AGI (ESICM WGAP grade III and IV vs grade II).

Most studies included in this meta-analysis reported a high prevalence of AGI in critically ill patients. However, the variation between estimates was high. As the prevalence of AGI depends heavily on the definitions applied, the disparity between studies likely resulted from the different criteria applied to identify AGI. In 2012, the ESICM WGAP recommended standardized criteria to define and grade the severity of AGI in critically ill patients. In the present review, the subgroup analysis of studies that applied the standardized ESICM WGAP criteria demonstrated that AGI occurs in approximately 50% of patients in critical care. In accordance with these findings, evidence suggests that almost 50% of patients admitted to the ICU have enterocyte damage.^[19]

In critically ill patients, AGI may manifest as delayed gastric emptying, changes in intestinal motility patterns, and impaired integrity of the intestinal barrier.^[1] Dysfunction in these processes decreases nutrient absorption, leading to malnutrition.^[20] AGI may also result from or augment systemic inflammatory reaction

(Newcastle-Ottawa quality assessment scale). ŝ

Selection

Selection of the

studie	
cluded	
the in	
ality of	
Quê	

				Risk Difference			Ris	Difference		
Study or Subgroup	Risk Difference	SE	Weight	IV, Random, 95% Cl	Year		IV. Ra	ndom. 95%		
4.2.1 AGI										
Chang 1987	0.466346	0.03459	8.3%	0.47 [0.40, 0.53]	1987				-	
Montejo 1999	0.6275	0.024174	8.4%	0.63 [0.58, 0.67]	1999				-	
Mentec 2001	0.457516	0.040276	8.3%	0.46 [0.38, 0.54]	2001					
Reintam 2006	0.097372	0.005828	8.5%	0.10 [0.09, 0.11]	2006					
Reintam 2008	0.655303	0.029251	8.4%	0.66 [0.60, 0.71]	2008					
SHIMIZU 2011	0.222222	0.052378	8.1%	0.22 [0.12, 0.32]	2011					
guyen 2013	0.201613	0.025477	8.4%	0.20 [0.15, 0.25]	2013			-		
Bejarano 2013	0.291667	0.053567	8.1%	0.29 [0.19, 0.40]	2013				-	
Reintam 2014	0.523949	0.01207	8.5%	0.52 [0.50, 0.55]	2014					
Gungabissoon 2014 Subtotal (95% CI)	0.305085	0.010597	8.5% 83.3%	0.31 [0.28, 0.33]	2014					
leterogeneity: Tau ² =	0.05; Chi ² = 1722.7	4, df = 9 (P	< 0.0000	1); $l^2 = 99\%$						
est for overall effect:	Z = 5.25 (P < 0.000	001)		144.1 - 49.600						
.2.2 AGI with ESICM	Definiton									
hang 2014	0.338346	0.041027	8.2%	0.34 [0.26, 0.42]	2014				-	
łu 2017	0.645455	0.020398	8.4%	0.65 [0.61, 0.69]	2017				-	
Subtotal (95% CI)			16.7%	0.49 [0.19, 0.79]						
leterogeneity: Tau ² =	0.05; Chi ² = 44.93,	df = 1 (P <	0.00001);	l ² = 98%						
est for overall effect:	Z = 3.22 (P = 0.001)								
otal (95% Cl)			100.0%	0.40 [0.27, 0.54]						
leterogeneity: Tau ² =	0.06; Chi ² = 2113.4	7, df = 11 (P < 0.000	01); l ² = 99%		-	1		0.5	-
est for overall effect:	Z = 5.76 (P < 0.000	001)				-1	-0.5	Draparti	0.5	
est for subaroup diffe	erences: Chi ² = 0.41	. df = 1 (P	= 0.52), I ²	= 0%				Proporti		

Figure 2. Incidence of AGI in critically ill patients. AGI = acute gastrointestinal injury, CI = confidence interval, ESICM = European Society of Intensive Care Medicine.

				Risk Difference			Risk	Difference
Study or Subgroup	Risk Difference	SE	Weight	IV. Random, 95% Cl	Year		IV. Ra	ndom. 95% Cl
Chang 1987	0.505155	0.050765	7.3%	0.51 [0.41, 0.60]	1987			
Montejo 1999	0.310757	0.029212	8.0%	0.31 [0.25, 0.37]	1999			-
Mentec 2001	0.414286	0.058877	7.0%	0.41 [0.30, 0.53]	2001			
Reintam 2006	0.436508	0.031242	7.9%	0.44 [0.38, 0.50]	2006			
Reintam 2008	0.202312	0.030542	7.9%	0.20 [0.14, 0.26]	2008			
SHIMIZU 2011	0.642857	0.12806	4.2%	0.64 [0.39, 0.89]	2011			
Bejarano 2013	0.428571	0.10799	5.0%	0.43 [0.22, 0.64]	2013			
Nguyen 2013	0.26	0.062032	6.8%	0.26 [0.14, 0.38]	2013			
Gungabissoon 2014	0.307292	0.019224	8.2%	0.31 [0.27, 0.34]	2014			-
Reintam 2014	0.125975	0.011079	8.3%	0.13 [0.10, 0.15]	2014			
Zhang 2014	0.422222	0.073628	6.3%	0.42 [0.28, 0.57]	2014			
Li 2016	0.264151	0.042822	7.6%	0.26 [0.18, 0.35]	2016			
Hu 2017	0.349296	0.025303	8.1%	0.35 [0.30, 0.40]	2017			-
Li 2017	0.185714	0.04648	7.4%	0.19 [0.09, 0.28]	2017			1000
Total (95% CI)			100.0%	0.33 [0.26, 0.41]				•
Heterogeneity: Tau ² =	0.02; Chi ² = 240.00), df = 13 (F	< 0.0000	1); l ² = 95%		<u> </u>	1-	
Test for overall effect:	Z = 8.83 (P < 0.000	001)				-1	-0.5	0 0.5 Proportion

Figure 3. Incidence of mortality in patients with acute gastrointestinal injury (AGI). CI = confidence interval.

syndrome and multiple organ dysfunction syndrome (MODS), in which the release of inflammatory mediators following trauma, surgery, infection, and hemorrhage causes intestinal flora translocation and injury to the intestinal mucus membrane, and results in loss of barrier function, an impaired immune-protective system, and secretion dysfunction.^[21,22] Some evidence suggests that the development of MODS is associated with a derangement in intestinal permeability, which is detectable before the onset of MODS,^[23] and that GI dysfunction serves as

the main driver of MODS in injured or critically ill patients.^[12] Interestingly, incremental organ failure in MODS results in a 20% increase in mortality.^[24] Similarly, in the present study, the mortality of AGI patients was significantly higher than that of non-AGI patients, and mortality increased in patients with GI failure, compared to patients with GI dysfunction.

Assessment of GI function is difficult because some of the symptoms are subjective and poorly defined,^[25] which may be one reason why studies on AGI in critically ill patients cannot be

	AGI		Non-A	GI		Risk Ratio			R	lisk Ratio		
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Random, 95% C	Year		M-H, R	andom. 95% Cl		
1.1.1 1												
Chang 1987	49	97	28	111	8.7%	2.00 [1.37, 2.92]	1987					
Montejo 1999	78	251	21	149	8.5%	2.20 [1.42, 3.41]	1999					
Mentec 2001	29	70	21	83	8.5%	1.64 [1.03, 2.60]	2001					
Reintam 2006	110	252	124	2336	8.9%	8.22 [6.59, 10.26]	2006			-		
Reintam 2008	35	173	4	91	6.8%	4.60 [1.69, 12.55]	2008				-	
SHIMIZU 2011	9	14	10	49	7.8%	3.15 [1.60, 6.20]	2011					
guyen 2013	13	50	73	198	8.4%	0.71 [0.43, 1.16]	2013		-	-		
Bejarano 2013	9	21	14	51	7.9%	1.56 [0.80, 3.04]	2013					
Reintam 2014	113	897	108	851	8.9%	0.99 [0.78, 1.27]	2014			+		
Gungabissoon 2014	177	576	177	576	9.0%	1.00 [0.84, 1.19]	2014			+		
Subtotal (95% CI)		2401		4495	83.2%	1.95 [1.06, 3.59]						
Total events	622		580									
		N 42 31 0 2		the state of the state		No. Construction of the second s						
Heterogeneity: Tau ² =	0.90; Chi ²	= 273.1	19, df = 9	(P<0	.00001); l ²	= 97%						
Heterogeneity: Tau ² = Test for overall effect: 2	0.90; Chi ² Z = 2.15 (I	= 273. P = 0.03	19, df = 9 3)	(P < 0	.00001); I²	= 97%						
Heterogeneity: Tau ² = Test for overall effect: 3	0.90; Chi ² Z = 2.15 (I	= 273. P = 0.03	19, df = 9 3)	(P < 0	.00001); I²	= 97%						
Heterogeneity: Tau ² = Fest for overall effect: : I.1.2 2 Zhang 2014	0.90; Chi ² Z = 2.15 (I 19	= 273.1 P = 0.03	19, df = 9 3) 12	(P < 0	.00001); I ² 8.0%	= 97% 3.10 [1.65, 5.80]	2014			_		
leterogeneity: Tau ² = Test for overall effect: 1.1.2 2 Chang 2014 Hu 2017	0.90; Chi ² Z = 2.15 (l 19 124	= 273.1 P = 0.03 45 355	19, df = 9 3) 12 37	(P < 0 88 195	8.0% 8.8%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54]	2014 2017			-		
Heterogeneity: Tau ² = Test for overall effect: : 1.1.2 2 /hang 2014 fu 2017 subtotal (95% CI)	0.90; Chi ² Z = 2.15 (l 19 124	= 273.1 P = 0.03 45 355 400	19, df = 9 3) 12 37	(P < 0. 88 195 283	8.0% 8.8% 8.8% 16.8%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63]	2014 2017					
leterogeneity: Tau ² = Test for overall effect: : 1.1.2 2 Zhang 2014 Hu 2017 Subtotal (95% CI) Total events	0.90; Chi ² Z = 2.15 (l 19 124 143	= 273.1 P = 0.03 45 355 400	19, df = 9 3) 12 37 49	(P < 0 88 195 283	8.0% 8.8% 8.8% 16.8%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63]	2014 2017			-		
Heterogeneity: Tau ² = Fest for overall effect: : I.1.2 2 Zhang 2014 Hu 2017 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² =	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ²	= 273.1 P = 0.03 45 355 400 = 2.10,	19, df = 9 3) 12 37 49 , df = 1 (F	(P < 0. 88 195 283 P = 0.15	8.0% 8.8% 16.8% j); l² = 529	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63]	2014 2017					
Heterogeneity: Tau ² = Test for overall effect: ; Zhang 2014 Hu 2017 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect; ;	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ² Z = 3.19 (l	= 273.7 P = 0.03 45 355 400 = 2.10, P = 0.00	19, df = 9 3) 12 37 49 , df = 1 (F 01)	88 195 283 2 = 0.15	8.0% 8.8% 8.8% 16.8% 5); l ² = 52%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63]	2014 2017			•		
Heterogeneity: Tau ² = Fest for overall effect: : I.1.2 2 Zhang 2014 Hu 2017 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = Fest for overall effect: : Fotal (95% CI)	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ² Z = 3.19 (l	= 273.* P = 0.03 45 355 400 = 2.10, P = 0.00 2801	19, df = 9 3) 12 37 49 , df = 1 (F	88 195 283 9 = 0.15 4778	8.0% 8.8% 8.8% 16.8% 5); I ² = 529 100.0%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63] 6 2.01 [1.20, 3.37]	2014 2017			•		
Heterogeneity: Tau ² = Test for overall effect: : 1.1.2 2 Zhang 2014 -lu 2017 Subtotal (95% CI) Fotal events -leterogeneity: Tau ² = Fest for overall effect: : Fotal (95% CI) Fotal events	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ² Z = 3.19 (l 765	= 273.* P = 0.03 45 355 400 = 2.10, P = 0.00 2801	19, df = 9 3) 12 37 49 df = 1 (F 01) 629	88 195 283 9 = 0.15 4778	8.0% 8.8% 16.8% 5); I ² = 52%	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63] 6 2.01 [1.20, 3.37]	2014 2017			•		
Heterogeneity: Tau ² = rest for overall effect: : 1.1.2 2 Zhang 2014 Hu 2017 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = rest for overall effect: : Fotal (95% CI) Fotal events Heterogeneity: Tau ² =	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ² Z = 3.19 (l 765 0.76; Chi ²	= 273.* P = 0.03 45 355 400 = 2.10, P = 0.00 2801 = 275.*	19, df = 9 3) 12 37 49 df = 1 (F 01) 629 17, df = 1	88 195 283 P = 0.15 4778 1 (P < 0	8.0% 8.0% 8.8% 16.8% 5); I ² = 529 100.0% 0.00001):	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63] 6 2.01 [1.20, 3.37] 1 ² = 96%	2014 2017			•	<u>t</u>	T
Heterogeneity: Tau ² = Fest for overall effect: : 1.1.2 2 Zhang 2014 Hu 2017 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = Fotal (95% CI) Fotal events Heterogeneity: Tau ² = Fotal (95% CI) Fotal events Heterogeneity: Tau ² = Fest for overall effect: :	0.90; Chi ² Z = 2.15 (l 19 124 143 0.07; Chi ² Z = 3.19 (l 765 0.76; Chi ² Z = 2.66 (l	= 273.* P = 0.03 45 355 400 = 2.10, P = 0.00 2801 = 275.* P = 0.00	19, df = 9 3) 12 37 49 df = 1 (F 01) 629 17, df = 1 08)	88 195 283 9 = 0.15 4778 1 (P < 1	8.0% 8.8% 16.8% 5); I ² = 529 100.0% 0.00001);	= 97% 3.10 [1.65, 5.80] 1.84 [1.33, 2.54] 2.22 [1.36, 3.63] 6 2.01 [1.20, 3.37] I ² = 96%	2014 2017	L	0.1	•	H 10 11	00

	AGI III	+IV	AGI	п		Risk Ratio		F	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% Cl	Year	М-Н.	Fixed. 95% Cl
Zhang 2014	8	12	11	33	9.2%	2.00 [1.07, 3.74]	2014		
Li 2016	15	42	13	64	16.1%	1.76 [0.93, 3.31]	2016		
Hu 2017	62	123	62	232	67.2%	1.89 [1.43, 2.49]	2017		
Li 2017	6	24	7	46	7.5%	1.64 [0.62, 4.34]	2017		
Total (95% CI)		201		375	100.0%	1.86 [1.48, 2.34]			•
Total events	91		93						1104
Heterogeneity: Chi ² =	0.16, df = :	3 (P = ().98); ² =	0%					1 10 10
Test for overall effect:	Z = 5.27 (P < 0.0	0001)					Favours [AGI III	+IV] Favours [AGI II]

Figure 5. Risk of mortality according to the grade of AGI severity. AGI = acute gastrointestinal injury, CI = confidence interval.

standardized. One study showed that a combination of the GI failure score and the Sequential Organ Failure Assessment (SOFA) score had good prognostic value in patients who were mechanically ventilated on admission to hospital and stayed in the ICU for longer than 24 hours. Another study found that an increasing number of GI symptoms independently predicted 28day mortality, but an additional dysfunction score that significantly improved the prognostic accuracy of the SOFA score could not be developed due to data set limitations, definition problems, or possibly because GI dysfunction was the secondary cause of other organ failure.^[25] In the present review, included studies defined GI dysfunction according to disparate criteria, which may explain the substantial heterogeneity in this meta-analysis. Conversely, there was no heterogeneity between the 4 studies that reported on the incidence of mortality stratified according to the grades of AGI severity identified by the ESICM

WGAP. Because of the lack of markers for the measurement of GI function, the definition of AGI proposed by the ESICM WGAP is based on GI symptoms; therefore, establishing objective criteria for diagnosing AGI remains an urgent unmet need.

This review was associated with several limitations. First, the number of included studies was small. In the future, large, multicenter prospective observational studies are required to accurately characterize AGI and understand its impact on the morbidity and mortality of critically ill patients. Second, there was substantial heterogeneity among the included studies. Therefore, our findings should be interpreted with caution. This heterogeneity may have arisen from the disparate criteria used across the included studies to define AGI. The establishment of the ESICM WGAP criteria as a standard may facilitate the diagnosis of AGI in critically ill patients. Third, publication bias was not assessed due to the small sample size. Last, the primary disease and comorbidities of patients were not considered in the present analysis. However, all included studies recognized AGI as an independent pathophysiology.

5. Conclusions

This meta-analysis demonstrated that AGI is common in critically ill patients, mortality in critically ill patients with AGI is high, and severity of AGI is associated with mortality. The widespread clinical use of standard criteria with a severity gradation will facilitate the diagnosis and management of AGI in critically ill patients.

Author contributions

Conceptualization: Hongxiang Li.

Data curation: Yao Fu.

Investigation: Lili Ding.

Methodology: Xuechao Dong.

Software: Yao Fu.

Supervision: Hongxiang Li.

Validation: Lili Ding.

Visualization: Dong Zhang.

Writing – original draft: Dong Zhang.

Writing – review and editing: Dong Zhang, Yuting Li, Hongxiang Li.

Hongxiang Li orcid: 0000-0002-1399-8039.

References

- [1] Reintam Blaser A, Malbrain ML, Starkopf J, et al. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med 2012;38:384–94.
- [2] Hu B, Sun R, Wu A, et al. Severity of acute gastrointestinal injury grade is a predictor of all-cause mortality in critically ill patients: a multicenter, prospective, observational study. Crit Care 2017;21:188.
- [3] Li H, Zhang D, Wang Y, et al. Association between acute gastrointestinal injury grading system and disease severity and prognosis in critically ill patients: a multicenter, prospective, observational study in China. J Crit Care 2016;36:24–8.
- [4] Li H, Chen Y, Huo F, et al. Association between acute gastrointestinal injury and biomarkers of intestinal barrier function in critically ill patients. BMC Gastroenterol 2017;17:45.
- [5] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009;3:e123.
- [6] Wells GA, Shea BJ, O'connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in metaanalysis. Appl Eng Agric 2014;18:727–34.

- [8] Chang RW, Jacobs S, Lee B. Gastrointestinal dysfunction among intensive care unit patients. Crit Care Med 1987;15:909–14.
- [9] Montejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med 1999;27:1447–53.
- [10] Mentec H, Dupont H, Bocchetti M, et al. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001;29:1955.
- [11] Reintam A, Parm P, Redlich U, et al. Gastrointestinal failure in intensive care: a retrospective clinical study in three different intensive care units in Germany and Estonia. BMC Gastroenterol 2006;6:19.
- [12] Reintam A, Parm P, Kitus R, et al. Gastrointestinal Failure score in critically ill patients: a prospective observational study. Crit Care 2008;12:R90.
- [13] Shimizu K, Ogura H, Asahara T, et al. Gastrointestinal dysmotility is associated with altered gut flora and septic mortality in patients with severe systemic inflammatory response syndrome: a preliminary study. Neurogastroenterol Motil 2011;23:e330–157.
- [14] Nguyen T, Frenette AJ, Johanson C, et al. Impaired gastrointestinal transit and its associated morbidity in the intensive care unit. J Crit Care 2013;28:537.e11-7.
- [15] Bejarano N, Navarro S, Rebasa P, et al. Intra-abdominal pressure as a prognostic factor for tolerance of enteral nutrition in critical patients. JPEN J Parenter Enteral Nutr 2013;37:352–60.
- [16] Reintam Blaser A, Starkopf L, Deane AM, et al. Comparison of different definitions of feeding intolerance: a retrospective observational study. Clin Nutr 2015;34:956–61.
- [17] Gungabissoon U, Hacquoil K, Bains C, et al. Prevalence, risk factors, clinical consequences, and treatment of enteral feed intolerance during critical illness. JPEN J Parenter Enteral Nutr 2015;39:441–8.
- [18] Zhang D, Dong L, Fu Y, et al. Evaluation of clinical application of ESICM acute gastrointestinal injury grading system: a single-center observational study. Chin Med J 2014;127:1833–6.
- [19] Piton G, Belon F, Cypriani B, et al. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. Crit Care Med 2013;41:2169–76.
- [20] Viteri FE, Schneider RE. Gastrointestinal alterations in protein-calorie malnutrition. Med Clin North Am 1974;58:1487–505.
- [21] Meakins JL, Marshall JC. The gastrointestinal tract: the "motor" of MOF. Arch Surg 1986;121:197–201.
- [22] Chen HS, Zhang HD, Li W, et al. Acute gastrointestinal injury in the intensive care unit: a retrospective study. Ther Clin Risk Manag 2015;11:1523–9.
- [23] Doig C, Sutherland LJ, Fick G, et al. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Mede 1998;158:444–51.
- [24] Zygun DA, Doig CJ. Vincent J-L. Measuring organ dysfunction. Yearbook of Intensive Care and Emergency Medicine 2002. S Berlin, Heidelberg: pringer Berlin Heidelberg; 2002;899–910.
- [25] Reintam Blaser A, Poeze M, Malbrain ML, et al. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. Intensive Care Med 2013;39:899–909.